Key Highlights

● Marker won a $16.2 million non-dilutive grant from the Texas cancer agency.

● The grant funds the Phase 2 APOLLO study of MT-601 in lymphoma.

● The stock traded around $0.85 before the jump.

● No new clinical data were reported alongside the grant.

Marker Therapeutics (NASDAQ:MRKR) shares soared during Thursday's session after the cell-therapy developer secured a $16.2 million non-dilutive grant from Texas's cancer research agency to fund a mid-stage lymphoma study.

The grant

Marker Therapeutics, a clinical-stage immuno-oncology company, said it had been awarded a $16.2 million grant from the Cancer Prevention and Research Institute of Texas, known as CPRIT. The money will fund the Phase 2 APOLLO study of MT-601, also known as neldaleucel, in patients with relapsed or refractory large B-cell lymphoma whose disease has progressed after CD19-directed CAR-T therapy, according to the company's announcement.

Shares soared in Thursday's trading on November 19, appearing among the biggest gainers in late-morning trading. The stock traded below $1, at around $0.85 before the jump, which means even small changes in price translate into large moves on a relative basis.

Why non-dilutive money matters

For a small biotech, how a trial is paid for can matter as much as the trial itself. Companies at Marker's stage often fund research by selling new shares, which spreads ownership more thinly across a larger share count. A grant is different: it is described as non-dilutive because it brings in cash without issuing new stock. That distinction tends to be watched closely by investors in micro-cap drug developers, where funding is frequently the biggest question mark.

CPRIT is a Texas state agency that funds cancer research and related programmes. Further detail on how and when the grant money will be paid out was not disclosed.

The science

Marker develops cell therapies for cancer, and MT-601 is the candidate being studied in APOLLO. The APOLLO study targets a particularly difficult patient group: people whose large B-cell lymphoma has returned or failed to respond after CAR-T therapy, a treatment that itself is generally used after other Options have been tried. For these patients, treatment choices are limited, which is why a dedicated study draws attention.

No new clinical data were reported alongside the grant. The announcement was about funding, and the stock's response reflects how much that funding means for a company of Marker's size.

A lonely gain

The move came in a session that was bruising for almost everything else. The Nasdaq Composite fell 550.69 points to 23,879.20, its lowest close since April according to market data. The S&P 500 lost ground for a sixth straight day, and the Dow Jones Industrial Average closed below 50,000 after a 1,101-point drop. Health care was among the weaker sectors, and the Russell 2000 Index of small companies shed 59.20 points to 2,655.11.

Markets had opened higher before turning lower around midday, after Anthropic (NASDAQ:ANT)'s record IPO began trading and faded. Soft economic data added to the gloom, with weekly jobless claims rising to 203,000 and the Philadelphia Fed Manufacturing index slumping to 6.3. Company-specific news, like Marker's grant, was one of the few things able to move stocks higher.

What to watch

Investors will look for updates on the timing of patient enrolment and the first readouts from APOLLO, along with any further detail on how the CPRIT funds will be disbursed. Because the stock trades under $1, it can be highly volatile, and price moves can be large in either direction. Intraday levels may differ from the close.